|
|
 |
|
Viewing report
|
|
|
|
Biomarkers: The Future of Next-Generation Drug R&D
Takeda Pacific, Sep 2008, Pages: 147
This report analyzes the hot global market for biomarkers and related assays or tests used in drug R&D. The study reviews this dynamic market by looking at drug research and development spending trends, M&As, alliances, major diseases, applications, tools, technologies, products and services. This report suggests the future direction of the market for biomarkers and related ‘-omic’ or pharmacogenomic (PGx) assays or tests used in the next-generation of drug R&D. This study sizes the world market and growth rate of biomarkers and assays for drug R&D spending to 2012.
Drug and biopharmaceutical developers face numerous challenges that are being helped with emerging business and technical strategies or approaches that utilize biomarkers to improve their chances of success. This business area is set for strong continued growth as biomarkers and assays in drug R&D enable new opportunities. This report estimates that this potential multi-billion dollar market will grow at strong double-digit rates over the five-year study period.
The study discusses ongoing regional government initiatives that are fostering worldwide development in biomarkers and personalized medicine opportunities. With the current group of more than 20-marketed personalized medicines and companion tests as a model, government drug regulators have already begun to change the labels of selected marketed drugs to use specific companion tests to predict patient drug response. Drug regulators are asking that drug makers use certain kidney safety biomarker assays in drug R&D. Their goal is to streamline commercializing new, safer, more effective drugs and co-developed companion predictive tests by integrating biomarkers and related pharmacogenomic (PGx), protein, imaging or other tests into the drug R&D critical path. The study discusses how clinical trials are undergoing important changes that integrate biomarkers and assays into the drug R&D process to provide more meaningful information in order for drug makers to make better product development decisions.
This study uses more than 51 figures and tables to illustrate its useful findings. The report offers detailed information including data tables about strategic technologies, M&As, alliances and so on. Thirty-four selected companies are profiled with details such as business overview, contacts, financial details and product information. This fully searchable PDF report helps busy readers save time. This report uses hyperlinks to help readers jump to Table of Content items or to text-linked Internet sites.
This must-have report would benefit people with job titles including: CEO, VPs, Director of Business Development, Research Directors, Entrepreneurs, Venture Capitalists, Investment Planners, Research Scientists, Consultants or Industry Analysts.
Customers who bought this item also bought
Biomarkers and Tests for Pharma/ Biotech R&D – Companies Products and WW Market, 2006-2011
Companion Biomarkers in Drug Development
Biomarker Technology Platforms for Cancer Diagnoses and Therapies
Biomarkers - Technologies, Markets and Companies
It's All About the Biomarkers: How 2008's Biomarker-Based Partnering Is Driving Personalized Medicine
Blood Biomarkers and Beyond: Biomarker and Diagnostic Opportunities in Cardiovascular Disease
Biomarkers - Advanced Technologies and Global Market (2009-2014)
Biomarkers and Related Tests for Molecular Diagnostics and Pharma/ Biotech R&D -- Companies Products and WW Market, 2004-2009
Biomarkers 2008
How Overcoming the Challenge of Biomarker Validation Can Pay Off for Drug and Diagnostic Developers
Advances in Biomarkers
Trends in the Commercialization of Biomarkers: Tests and Companies
|
|
|
|
